These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
147 related items for PubMed ID: 33008561
1. Prostaglandin-Associated Periorbitopathy in Children and Young Adults with Glaucoma. Kim JS, Blizzard S, Woodward JA, Leyngold IM, Liss J, Freedman SF. Ophthalmol Glaucoma; 2020; 3(4):288-294. PubMed ID: 33008561 [Abstract] [Full Text] [Related]
4. Periorbital changes associated with prostaglandin analogs in Korean patients. Kim HW, Choi YJ, Lee KW, Lee MJ. BMC Ophthalmol; 2017 Jul 17; 17(1):126. PubMed ID: 28716077 [Abstract] [Full Text] [Related]
5. Periocular skin hyperpigmentation in children treated with prostaglandin analogues. Al-Zobidi M, Khandekar R, Craven ER, Hanafi S, Edward DP. J AAPOS; 2015 Feb 17; 19(1):49-53. PubMed ID: 25727587 [Abstract] [Full Text] [Related]
6. Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients. Patradul C, Tantisevi V, Manassakorn A. Asia Pac J Ophthalmol (Phila); 2017 Feb 17; 6(3):238-242. PubMed ID: 28379653 [Abstract] [Full Text] [Related]
11. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Clin Exp Ophthalmol; 2014 Mar 17; 42(2):126-31. PubMed ID: 23844550 [Abstract] [Full Text] [Related]
12. Prostaglandin analogues: A double-edged sword in orbital glaucoma disease management. Joganathan V, Cannon PS, Mercieca K. Eur J Ophthalmol; 2021 May 17; 31(3):NP40-NP44. PubMed ID: 32043370 [Abstract] [Full Text] [Related]
13. Observations on Prostaglandin Orbitopathy. Custer PL, Kent TL. Ophthalmic Plast Reconstr Surg; 2016 May 17; 32(2):102-5. PubMed ID: 25719374 [Abstract] [Full Text] [Related]
16. Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs. Duman N, Duman R, Yavaş GF, Doğruk Kaçar S, Özuğuz P, Çetinkaya E. Cutan Ocul Toxicol; 2017 Mar 17; 36(1):9-11. PubMed ID: 26911512 [Abstract] [Full Text] [Related]
17. Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment. Abalo-Lojo JM, Ferreiro PV, Asorey MK, Colmenero AE, Gonzalez F. Turk J Ophthalmol; 2023 Feb 24; 53(1):8-12. PubMed ID: 36847619 [Abstract] [Full Text] [Related]
18. In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma. DI Staso S, Agnifili L, Cecannecchia S, DI Gregorio A, Ciancaglini M. In Vivo; 2018 Feb 24; 32(2):211-220. PubMed ID: 29475902 [Abstract] [Full Text] [Related]
19. [Side-effects and risk profile of latanoprost 0.005% (Xalatan)]. Schlote T. Ophthalmologe; 2002 Sep 24; 99(9):724-9. PubMed ID: 12219263 [Abstract] [Full Text] [Related]
20. Pretarsal skin height changes in children receiving topical prostaglandin analogue therapy for primary congenital glaucoma. Al-Zobidi M, Khandekar R, Cruz A, Craven RE, Souru C, Malik R, Edward DP. J AAPOS; 2018 Aug 24; 22(4):290-293.e1. PubMed ID: 29792934 [Abstract] [Full Text] [Related] Page: [Next] [New Search]